Clinical Trials Directory

Trials / Completed

CompletedNCT00003873

Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer

Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
950 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Randomized phase III trial to compare the effectiveness of fluorouracil given by infusion with that of fluorouracil plus eniluracil given by mouth in treating patients who have metastatic, recurrent, or residual advanced colorectal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if fluorouracil is more effective with or without eniluracil for advanced colorectal cancer

Detailed description

OBJECTIVES: I. Compare the response rate, response duration, and survival of patients with advanced colorectal cancer treated with oral fluorouracil (5-FU) and eniluracil or with protracted infusion 5-FU. II. Compare the toxicity of these treatment regimens in this patient population. OUTLINE: This is a randomized study. Patients are stratified according to performance status (0 vs 1-2) and measurable disease (yes vs no). Patients are randomized to one of two treatment arms. ARM I: Patients receive fluorouracil IV as a continuous infusion for 28 days. ARM II: Patients receive eniluracil/fluorouracil orally twice a day for 28 days. Treatment continues every 35 days in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 10 weeks for 1 year.

Conditions

Interventions

TypeNameDescription
DRUGfluorouracilGiven IV or orally
DRUGeniluracilGiven orally

Timeline

Start date
1999-04-01
Primary completion
2007-07-01
First posted
2004-07-16
Last updated
2013-01-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00003873. Inclusion in this directory is not an endorsement.